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Our studies investigating the existence of tumor-initiating cell (TIC) populations in human esophageal squamous
cell carcinoma (ESCC) had identified a subpopulation of cells isolated from ESCC patient-derived tumor specimens
marked by an ALDHbri+ phenotype bear stem cell-like features. Importantly, KDM4C, a histone demethylase was
enhanced in ALDHbri+ subpopulation, suggesting that strategies interfering with KDM4C may be able to target
these putative TICs. In the present study, by genetic and chemical means, we demonstrated that, KDM4C
blockade selectively decreased the ESCC ALDHbri+ TICs population in vitro and specifically targeted the TICs in
ALDHbri+-derived xenograft, retarding engraftment. Subsequent studies of the KDM4C functional network
identified a subset of pluripotency-associated genes (PAGs) and aldehyde dehydrogenase family members to be
preferentially down-regulated in KDM4C inhibited ALDHbri+ TICs. We further supported a model in which KDM4C
maintains permissive histone modifications with a low level of H3K9 methylation at the promoters of several PAGs.
Moreover, ectopic expression of SOX2 restored KDM4C inhibition-dependent ALDHbri+ TIC properties. We
further confirmed these findings by showing that the cytoplasmic and nuclear KDM4C staining increased with
adverse pathologic phenotypes and poor patient survival. Such staining pattern of intracellular KDM4C appeared to
overlap with the expression of SOX2 and ALDH1. Collectively, our findings provided the insights into the
development of novel therapeutic strategies based on the inhibition of KDM4C pathway for the eliminating of
ESCC TIC compartment.
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TICs are thought to be resistant to current chemotherapeutic strategies
due to their intrinsic stem-like properties and thus may provide the
principal driving force behind recurrent tumor growth [1]. ESCC is one
of the most aggressive types of human cancer, known for its high
metastatic potential, enhanced heterogeneity and resistance to
conventional therapy at advanced stages [2]. In this perspective, the
aim of this study was to use human ESCC cell lines and patient-derived
tumor specimens to identify and characterize putative ESCC TIC
population. Further, to investigate the underlying molecular mecha-
nism by which this population mediates ESCC maintenance.
Chromatin-associated proteins are essential for the specification and
maintenance of cell identity. Histone demethylases constitute a large
and diverse family of enzymes, which is regarded as an important type of
histone modification during TICs maintenance [3]. The KDM4
subfamily (KDM4A-D) comprises the recently discovered Jumonji C
(JmjC) domain containing (JMJD) histone demethylases, which
demethylates mainly H3K9me2/3 or H3K36me3 [4]. A number of
reports addressing the functions of the KDM4 demethylases showed
that subunits are structurally similar and sequence homologous [4,5]
but may differ in their substrate specificity [6,7], implying they may
have widespread and redundant functions as well as unique targets and
distinct biological roles. As there is increasing evidence that KDMs are
associated with various disease states, they have emerged as attractive
targets for the development of new therapeutic drugs [8,9]. Efforts by
many groups to find lysine demethylase inhibitors have led to the
identification of several classes of inhibitors [10–12].
KDM4C, also known as JMJD2C/GASC1, is a member of the
KDM4 subgroup of JmjC domain-containing proteins which catalyzes
the demethylation of tri- and dimethylated lysine 9 and lysine 36 on
histoneH3. KDM4Cwas first identified as an oncogene that is amplified
in esophageal cancer cell line, KYSE-150 [13]. Recent studies have
implicated a role for KDM4C in self-renewal and pluripotency in
preimplantation embryos and embryonic stem (ES) cells [14–16]. So far,
the specific roles of KDM4C involved in maintenance of ESCC TICs or
whether it can be used for TIC-directed therapy are largely unexplored.
Previous report identified ALDH1 as a marker of TICs in a broad
spectrum of malignancies as assessed by the Aldefluor assay [17–19].
In this study, we used the similar techniques to identify cellular
hierarchies in characterized ESCC cell line and patient-derived
dissociated tumor specimens and demonstrated that a subset of cells
contained ALDHbri+ components which endowed with stem cell
properties as evidenced in clonogenicity self-renewal and are more
tumorigenic in vivo. Further, we reported here that KDM4C
blockade using either lentiviral-mediated gene silencing or its
pharmacological inhibitor Caffeic acid (CaA) [20], preferentially
reduced the proportion of ALDHbri+ cells, providing evidence for its
roles in the maintenance of TICs in ESCC. Furthermore, we have
identified several pluripotency-related genes and diverse members of
aldehyde dehydrogenase family to be downstream targets of KDM4C.
Our study highlighted the role of the KDM4C in the maintenance
of TICs in ESCC and probed the therapeutic potential of targeting
KDM4C pathway activity in human ESCC.
Material and Methods
Fresh Clinical Tissue Specimen Collection and Processing
ESCC clinical samples were collected in the period between March
2008 and February 2010 from Anyang Cancer Hospital (Henan,China). All samples were approved by the committee for ethical
review of research involving human subjects at The First Affiliated
Hospital of Henan University of Science and Technology (Luoyang,
China).
A portion of the samples (EC-1, 2, 3) were received in the laboratory
immediately mechanically disaggregated and digested as described in
Supplementary and subsequently incubated with Aldefluor® kit [17].
The resultant tumor cells were injected subcutaneously at different
multiplicities, in the range 104–102(‘limiting dilution’), into
NOD-SCID mice or seeded for the Esosphere formation assay
(Supplemental Material and Methods).
Chromatin Immunoprecipitation Assay
ChIP assay was carried out as described previously [21]. Chromatin
extracts were immunoprecipitated using 10 μg anti-KDM4C
(A300-885 A; Bethyl Laboratories); 4 μg anti-trimethylated H3K9
(61,013; Active Motif), 4 μg anti-dimethylated H3K9 (39,683;
Active Motif), and 2 μg anti-total H3 (39,763; Active Motif);
Anti-GST (sc-459; Santa Cruz Biotechnology) antibodies were used
as mock ChIP controls. Fold enrichments were calculated by
determining the ratios of the amount of immunoprecipitated DNA
to that of the input sample and were normalized to the level observed
at a control region, which was defined as 1.0. The ChIP primers are
available on request (Supplemental Table Primers).
Microarray Analysis and Gene Ontology Analysis
We performed transcriptome analysis by Agilent Human Whole
Genome Microarrays in 48 hours KDM4C knockdown (or
CaA-treated) and control ALDHbri+ ESCC TICs isolated from the
ESCC clinical samples. The genes that decreased by ≥20% following
KDM4C knockdown in primary ESCC TICs were analyzed by the
DAVID Functional Annotation Tool, compared with a background
of the total genes expressed in ALDHbri+ ESCC cells.
AlphaLISA Assay
The AlphaLISA Tri-Methyl-Histone H3 Lysine9 (H3K9me3)
Cellular Detection Kit was obtained from PerkinElmer Life Sciences.
Cells were cultured in 6-well tissue culture plates at 3 × 105/well in
3 ml of media for 12 h, then incubated with different concentrations
of CaA (Sigma-Aldrich) for another 48 h. The same volume of
DMSO was used as the vehicle control for CaA experiments at a final
concentration of 0.1%. The luminescence signal was measured using
the Envision (PerkinElmer Life Sciences) plate readers.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 5.0
software using t-test. Data are presented as the mean ± SEM. P ≤ .05
was regarded as being statistically significant.
Results
KDM4CLevels are FrequentlyUp-Regulated in a Subset of Patient-
Derived Primary ESCC Cultures and Established Cell Lines
To investigate the role of KDM4C in the development of ESCC,
we first examined KDM4C expression in well-characterized human
ESCC cell lines, patient-derived ESCC tumors under conditions that
permitted expansion in vitro and the normal human immortalized
epithelial cells using Western blotting assay. Expression of KDM4C
proteins were clearly detected in 3 of 5 established ESCC cell lines
(EC9706, KYSE-150, KYSE-30, Figure S1A) and 3 of 5 primary
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documented at low level in one normal human Immortalized
epithelial cells (SHEE, Figure S1A).
We designed eight shRNAs directed against KDM4C and infected
ESCC cells with lentiviral particles encoding shRNA sequences.
KDM4C-shRNA-5 (shKDM4C) was employed for most studies, as it
reliably yielded cells with N80% KDM4C knockdown at the protein
levels. KDM4C-shRNA-7 was used as a second shRNA to confirm
the KDM4C knockdown phenotype (Figure S1C).
KDM4C Expression is Enhanced in ALDHbri+ Subpopulation
which is Critical for the Maintenance of ESCC TICs
To determine whether ESCC contains TIC population, cells from
KYSE-150 cell line and patient-derived dissociated tumors of ESCC
were isolated by virtue of ALDH activity. Representative cytograms
are shown in Figure 1A, the ALDHbri+ populations, ranging from
3.92% to 15.6%, were detected in all cell preparations from freshly
isolated ESCC specimens. The ALDHbri+ fraction of KYSE-150 cell
line was approximately 0.97%. These experiments confirmed the
presence of ALDHbri+ cells in human ESCC.
To determine whether the subset defined by high ALDH activity
(ALDHbri+) was enriched in TIC, we compared the ability of
FACS-sorted ALDHbri+ ESCC cells and their ALDHlow- counter-
parts to generate esospheres in vitro and to initiate tumor formation
in vivo.
Within 7 days of culture of ALDHbri+ and their ALDHlow-
daughter cells in non-adherent, serum-free, growth factor-
supplemented conditions. As previously reported, these culture
conditions allowed the selection of undifferentiated cancer stem
and progenitor cells, while serum-dependent differentiated tumor
cells and non-transformed accessory cells were negatively selected
[22]. The ALDHbri+ population was capable of generating more
esospheres at a density of 5000 cells/ml than its ALDHlow-
counterpart (Figure 1, B and C). Moreover, ALDHbri+ cells sorted
from dissociated esospheres were capable of self-renewal in vitro as
evidenced by similar ALDHbri+ population percentage (Figure 1D)
and esosphere-initiating capacity in serial propagations (Figure 1, E
and F), showing virtually unlimited growth potential.
Next, we investigated the ability of sorted cells to subcutaneously
engraft and give rise to tumors by inoculation of limiting dilutions of
cells (ranging from 102 to 104) into mammary fat pads of NOD/
SCID mice.
As shown in Table I, using cells from patient EC-1, the sorted
ALDHbri+ cells clearly showed increased tumor-forming capacity
comparing with ALDHlow- and bulk counterparts when 104 or fewer
cells were implanted, which was evident at extremely low
multiplicities (i.e., 102 transplanted cells). Indeed, 104 ALDHbri+
cells formed tumors in 5/5 mice, compared to 2/5 and 4/5 mice with
tumors from matched ALDHlow- and unsorted cells, respectively. 103
ALDHbri+ cells formed tumors in 5/5 mice, whereas 0/5 and 2/5 mice
bear tumors when implanted with same matched ALDHlow- and
unsorted cells, respectively. When mice were implanted with 102
cells, ALDHbri+ cells formed tumors in 2/5 mice, compared to no
tumor formation from matched ALDHlow- and unsorted cells.
In addition to their increased tumor-forming capacity, the
frequency of TICs was considerably higher in ALDHbri+ cells (1 in
32) than ALDHlow- cells (1 in 2704) or parental cells (1 in 979)
(Table I). For comparison of tumor latency, the ALDHbri+ fraction
was capable of generating tumors following injection of as few as 102cells whereas about 104 ALDHlow- cells were needed for generating
tumors in the same time period (Figure 2A). Tumor formation in the
lower dilutions for ALDHlow- cells was either significantly delayed or
undetected within the 2-month experimental time frame (Figure 2A).
As indicated, tumor growth kinetics correlated with the latency and
size of tumor formation correlated with the number of ALDHbri+
cells injected (Figure 2A).
In subsequent experiments, we found that ALDHbri+ cells from
samples EC-2 and EC-3 were also enriched for high tumorigenicity
even at low cell input numbers. ALDHbri+ cells purified from EC-2
and EC-3 were tumorigenic at 100 cells, and resulted in tumor
formation in 2/5 and 4/5 mice, respectively. In contrast, 1000
ALDHlow- cells from both EC-2 and EC-3 were essentially
non-tumorigenic, with tumor formation in only 1/5 and 2/5 mice.
We were unable to grow tumors with 100 or fewer ALDHlow- sorted
cells from the primary EC-2 and EC-3 tumors (Table II and III).
Using the IVIS imaging system, we monitored xenograft formation
by measuring the change in bioluminescence signal and found that
luciferase-tagged ALDHbri+ cells exhibited a greater frequency of
tumor formation, particularly at low numbers of injected cells,
compared to ALDHlow- counterparts (Figure 2B).
To investigate whether ALDHbri+ ESCC cells have long-term
tumorigenic potential and self-renewing capacity, we evaluated their
ability to generate tumors in serial transplantations. Tumors obtained
by subcutaneous transplantation of both ALDHbri+ and ALDHlow-
cells from primary xenografts were again reduced to single-cell
suspension, sorted again by FACS into ALDHbri+ and ALDHlow-
fractions, and again transplanted (104cells) into recipient mice.
Table IV summarizes the results relative to a total of three rounds of
serial transplantations. Clearly, whereas ALDHlow- rapidly lost their
tumor-initiating capacity already after two rounds, ALDHbri+ cells
demonstrate self-renewal by retaining their ability to engraft
throughout the serial transplantation passages.
Finally, to determine the abilities of the ALDHbri+ cells to
re-establish tumor heterogeneity in vivo revealed ALDHbri+-derived
xenografts contained a mixed population with 10.1% and 14.7% of
ALDHbri+ cells similar to their original tumors of EC-2 and EC-3
(Figure 2C). Moreover, tumors formed by ALDHbri+ cells contained
histological and antigenic (KDM4C) features closely resembling the
original tumor, as shown by hematoxylin and eosin (H&E) staining
and IHC analysis (Figure 2D). These suggested that a heterogeneous
tumor phenotype was recapitulated following injection of a fraction of
ALDHbri+ cells.
We subsequently tested the expression of KDM4C in sorted
ALDHbri+ TICs and ALDHlow- tumor cells from three ESCC
specimens by qPCR (Figure S2A) and Western blotting assay
(Figure S2B). KDM4C expression was enriched in the ALDHbri+
subpopulation as compared with the ALDHlow- counterparts. In
light of this commonality between sorted subpopulations, we
hypothesized that KDM4C is involved in the maintenance of
human ESCC ALDHbri+ cells.
KDM4C InhibitionDecreases the Clonogenicity and Self-Renewal
of ALDHbri+ ESCC TICs
We next tested whether KDM4C function was involved in
maintenance of the ALDHbri+ ESCC TICs. Silencing of KDM4C
was achieved by lentiviral expression of shRNAs (Figure S2C).
Aldefluor analysis revealed KDM4C knockdown led to a drastic
decrease in the fraction of ALDHbri+ subpopulation from 9.8% to
Figure 1. A subset of ESCC cells contained ALDHbri+ components which endowed with stem cell properties as evidenced in
clonogenicity and self-renewal in vitro. (A) Representative Aldefluor analysis in primary patient-derived ESCC cells and KYSE-150 cell line.
Control samples incubated with the inhibitor, DEAB, were used to ensure identification of ALDHbri+ and ALDHlow- cells. (B) Sphere
formation efficiency of fluorescence-activated cell sorting (FACS)-sorted ALDHbri+ and ALDHlow- cells isolated from fresh samples and
cell lines. (C) Representative images of ALDHbri+ and ALDHlow- derived spheres of EC-2 (scale bar = 50 μm). (D) Representative Aldefluor
analysis in dissociated esospheres of EC-2 in serial propagations. Control samples incubated with the inhibitor, DEAB, were used to
ensure identification of ALDHbri+ and ALDHlow- cells. (E) Representative images of ALDHbri+ and ALDHlow- spheres of EC-2 in three
passages (scale bar = 50 μm). (F). ALDHbri+ and unseparated subpopulations of EC-2 were capable of self-renewal in vitro, as shown by
similar esosphere-initiating capacity in three passages.
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Figure 2. Asubset of ESCCcells containedALDHbri+ componentswhichwere tumorigenic in vivo. (A) Tumorigenesis of ALDHbri+ andALDHlow- in
NOD/SCID mice. Tumor growth curves were plotted for the numbers of engrafted cells (10,000, 1000, and 100 cells) and for each subpopulation
(ALDHbri+ andALDHlow-). Tumorgrowthkineticscorrelatedwith the latencyandsizeof tumor formationand thenumberofALDHbri+ cells.No tumor
was detected at the ALDHlow- cells' injection site (100 cells injected). Data represent mean ± SEM (n = 3). P b .05 compared with ALDHlow-.
(B) Representative bioluminescent images of mice harboring tumors are shown. To evaluate the tumorigenesis of ALDHbri+ and ALDHlow- in vivo,
we infected both cells with a lentivirus expressing luciferase, and inoculated 10,000, 1000 and 100 luciferase-tagged cells into NOD/SCID mice.
Tumor formationwasmeasured atweekly intervals following inoculation, revealed a statistically significant increase (P b .01) in tumoral formation in
ALDHbri+ compared with ALDHlow- cells. (C) Differentiation of ALDHbri+ and ALDHlow- cells in vivo. Sorted ALDHbri+ and ALDHlow- cells from EC-2
andEC-3were implanted intoNOD/SCIDmice and the xenografts derived fromALDHbri+ and those fromALDHlow- cellswere analyzedbyAldefluor
assay. (D)HistologyandKDM4C IHCanalysisofprimary tumorand tumorxenograft generated fromALDHbri+ cells isolated fromEC-2andEC-3. The
ALDHbri+ population was capable of regenerating the phenotypic heterogeneity of the initial tumor after a passage in NOD/SCID mice.
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small ALDHbri+ population that was reduced from 3.92% to 0.09%
(Figure 3A). Moreover, repression of KDM4C expression in ALDHbri+TICs significantly suppressed the ability of cells to initiate esospheres
when grown in non-adherent serum-free conditions in vitro (Figure 3B)
and expand in subsequent in vitro serial propagations (Figure 3C).
Figure 3. KDM4C inhibition decreased the percentage, clonogenicity and self-renewal of ESCC ALDHbri+ TICs in vitro. (A) Quantification
of the fraction of ALDHbri+ cells, determined by Aldefluor assay in patient-derived ESCC cells transduced with LV-c, LV-shKDM4C-5 or
LV-shKDM4C-7. Significant reduction in the percentage of ALDHbri+ cells after silencing of KDM4C is shown. (B) Representative images
of spheres formed by patient 2-derived ALDHbri+ TICs transduced with LV-c, LV-shKDM4C-5 or LV-shKDM4C-7. (Scale bar = 50 μm).
Decreased Number and size of spheres are shown in ALDHbri+ cells after silencing of KDM4C. (C) ALDHbri+ cells were capable of
self-renewal in vitro, as shown by similar esosphere-initiating capacity in three passages of EC-2. Significant reduction in the self-renewal
of ALDHbri+ cells after silencing of KDM4C is shown. (D) Quantification of the fraction of ALDHbri+ cells, determined by Aldefluor assay in
patient-derived ESCC cells treated with vehicle, 5 μM, 10 μM or 20 μM KDM4C inhibitor CaA. Significant reduction in the percentage of
ALDHbri+ cells after CaA treatment is shown. (E) Representative images of spheres formed by patient 2-derived ALDHbri+ cells treated
with vehicle, 5 μM, 10 μM or 20 μMCaA. (Scale bar = 50 μm). Decreased Number and size of spheres are shown in ALDHbri+ cells upon
CaA treatment in a dose-dependent manner. (F) ALDHbri+ cells of EC-2 were capable of self-renewal in vitro, as shown by similar
esosphere-initiating capacity in serial passages. Significant reduction in the self-renewal of ALDHbri+ cells after CaA treatment is shown.
Data shown are the mean ± S.E.M. of at least three independent experiments. *P⩽0.05; **P⩽0.01.
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function, we inhibited it pharmacologically. The pharmacologicalinhibitor CaA treatment dramatically diminished the percentage of
ALDHbri+ population, from 9.8% to 7.93% (5 μM) and 1.22%
Figure 4. The KDM4C inhibitor CaA preferentially abolished TIC in ALDHbri+-derived xenograft model in vivo. (A) Representative images of
subcutaneous xenografts in nudemice taken at the same time for each group. For each xenograft, 10,000 cellswere injected into themammary
fat pad of nude mice. There is a statistically significant size reduction of the tumors treated with 5 mg/kg or 10 mg/kg CaA compared with the
control tumors (P b .01, respectively). (B) Tumor growth curves were plotted for the numbers of engrafted cells (10,000 FACS-sorted ALDHbri+
cells). There is a statistically significant size reduction of the tumor treated with 5 mg/kg or 10 mg/kg CaA compared with the controls during
the course of each indicated time points (P b .01, respectively). (C) Mice bearing injection were treatedwith either vehicle or CaA (5mg/kg or
10mg/kg) three times aweek for a total of 8weeks. Cellswere dissociated from tumors and subject to Aldefluor assay. Shown are cytograms of
percentALDHbri+ cells. (D) Xenotransplants fromeachgroupwere collected, andALDH1 IHCstainingwasdone.CytoplasmicALDH1expression
was detected in the controls (arrowheads denote positive staining), whereas low expression was detected in the tumors treated with CaA.
(E) Representative bioluminescent images ofmice harboring tumors are shown (Upper panel). To evaluate the effect of CaA treatment on tumor
initiation, we infected ALDHbri+ cells with a lentivirus expressing luciferase, and inoculated 10,000 luciferase-tagged cells into NOD/SCIDmice.
Oneweek after the initial tumor inoculation, tumor-bearing animalswere begun administered intraperitoneallywith CaA (5mg/kg or 10mg/kg) or
saline controls three times aweek for a total of 8 weeks. Tumor formationwasmonitored using bioluminescence imaging. Quantification of the
normalized photon flux (Lower panel), measured at weekly intervals following inoculation, revealed a statistically significant decrease (P b .01,
respectively) in tumoral formation in CaA-treated compared with controls for mice inoculated with luciferase-tagged ALDHbri+ cells.
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Figure 5. Profiling of KDM4C knockdown and control ALDHbri+ ESCC TICs. (A) Venn diagrams for genes that are down-regulated by
KDM4Csh knockdown or CaA treatment. ALDHbri+ cells were treated with shKDM4C or CaA. The mRNA levels in KDM4C-depleted cells
were measured by Agilent Human Whole Genome Microarrays and compared with those in the controls. (B) Heatmap shows
unsupervised clustering of down-expressed transcripts obtained for the ALDHbri+ ESCC cells after KDM4C knockdown (right) or mock
transfection (left) using Agilent Human Whole Genome Microarrays. Colored spots indicate up-regulated (red) or down-regulated (blue)
genes from microarray analysis. (C) Heatmap shows Gene ontology analysis of genes that are co-down-regulated by KDM4C knockdown
and CaA treatment. Gene ontology analysis was performed using the program DAVID. (D) qPCR validation of differentially expressed
genes. Expression levels were normalized to GAPDH. White and black and bars represent expression in controls and KDM4C knockdown
ALDHbri+ cells, respectively (P b .01, respectively). (E) Immunostaining of control and KDM4C-shRNA ALDHbri+ cells. KDM4C-shRNA
cells have decreased KDM4C, SOX2 and ALDH1 expression relative to control cells. Nuclei were stained with DAPI. (Scale bar = 50 μm).
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(20 μM) in EC-3. The EC-1 had a small ALDHbri+ population that
was reduced to 2.19% and 0.06% by 5 and 20 μM CaA, respectively
(Figure 3D). We then examined the ability of CaA to block esospheres
formation. ALDHbri+ TICs from primary cell cultures seeded and
allowed to establish initial esospheres were then treated with vehicle, 5
μM, 10 μM, or 20 μM drug for an additional 7 days and the resulting
esospheres were analyzed. Esospheres formation was inhibited in a
dose-dependent manner, with a statistically significant 25% reductionin colonies grown in 5 μM CaA (P = .02) and an approximately 50%
and 95% reduction in colonies grown in 10 μM and 20 μM CaA
(P b .0001, respectively) (Figure 3E). After 7 days of CaA treatment,
esospheres were dissociated and the ability of single cells to generate
secondary spheres in absence of the drug was quantified. Consistently
with shRNA approach, CaA treatment also led to a significant and
dose-dependent reduction of the ability to form secondary spheres
(Figure 3F). Taken together, our results indicate that KDM4C is
required for the maintenance of the ALDHbri+ ESCC TICs in vitro.
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Xenograft Model In Vivo
We subsequently determined whether KDM4C is required for
TIC maintenance in vivo. ALDHbri+ TICs were injected subcutane-
ously in the mammary fat pads of NOD/SCID mice to initiate
xenograft tumors. One week after the initial tumor inoculation,
tumor-bearing animals were begun administered intraperitoneally
with CaA (5 mg/kg or 10 mg/kg) or saline controls three times a week
for a total of 8 weeks. For each xenotransplant, we observed
significant inhibition of tumor initiation by the small-molecule
inhibitor, as indicated by decreases in tumor size (Figure 4A) and
increases in tumor latency (Figure 4B).
After 8 weeks of treatment, animals were sacrificed, residual xenograft
tumors were harvested and dissociated into single cells and subjected to
Aldefluor assay without further compound treatment. Results showed
that residual controls contained an unchanged proportion of ALDHbri+
cells compared with parental tumor from which these ALDHbri+ cells
have been derived. In contrast, CaA treatment caused significant
reduction of the proportion of ALDHbri+ cells to 4.1% (5 mg/kg) and
0.29% (10 mg/kg), respectively (Figure 4C). These observations were
confirmed by IHC of ALDH1 expression in the different xenotrans-
plants, a decrease in ALDH1 staining was detected in CaA-treated
tumors compared with controls (Figure 4D). We also monitored
xenograft formation by in vivo imaging system (IVIS) and found that
CaA treatment greatly hampered the tumor initiating capability of the
luciferase-tagged ALDHbri+ cells (Figure 4E).
To further demonstrate that CaA treatment was able to reduce the
ESCC TIC population, we used a functional in vivo assay consisting
of re-implantation of equal cells from treated tumors into secondary
recipients. Tumor cells derived from controls showed similar tumor
re-growth at 104ALDHbri+ cells in secondary recipients. In contrast,
when equal numbers of cells were injected, those from CaA-treated
animals showed a 2- to 5-fold reduction in tumor incidence in
secondary recipients (Table V).Figure 6. Increased H3K9 methylation levels at the pluripotency-assoc
cells. ChIP assays were performed on ALDHbri+ cells followin
KDM4CshRNA-5, KDM4CshRNA-7) or exposure or not exposure t
collected for ChIP analyses using antibodies to the indicated H3K9 me
c-Myc, and Pou5f1 promoters. (A) Representative agarose gels showin
region is shown. Specific antibodies that individually recognize eithe
were used. GST antibody was used as a control. (B) ChIP analysis
inhibition as quantified by real-time PCR. Relative promoter occupan
(SEs) calculated from at least three replicates. The input signal is
Representative agarose gels showing PCR amplification products
antibodies that individually recognize either the di- or the trimethylate
levels at the c-Myc promoter after KDM4C inhibition as quantified by
SOX2 promoter after 48 h of exposure or not exposure to CaA for va
Relative promoter occupancies (%input) by the indicated H3K9methy
at least three replicates. (F) ChIP analysis of H3K9 methylation levels a
for various concentrations, as indicated, as quantified by real-time P
blot analysis and IHC staining(H) were done. Representative immunob
extracts from ALDHbri+-derived xenograft treated with or without CaA
CaA-treated xenografts compared with controls. β-Actin was used as
paraffin sections of CaA-treated xenografts analyzed by IHC. Sectio
increase in nuclear H3K9me3 methylation and decrease in SOX2 im
(arrowheads denote positive staining).Together, these studies demonstrate that CaA treatment
specifically targets and reduces the ESCC ALDHbri+ TIC
population.
KDM4C, Influences Unique Gene Signatures and Functional
Networks in ALDHbri+ ESCC TICs
To understand the molecular basis of the KDM4C function in
ALDHbri+ ESCC TICs maintenance, we performed transcriptomic
analyses by Agilent Human Whole Genome Microarrays in 48 hours
KDM4C knockdown and control ALDHbri+ ESCC TICs isolated
from the ESCC clinical samples. By evaluating the overlap between
down-regulated genes identified in CaA-treatment study and RNA
interference screen, we identified 694 genes that were commonly
down-regulated at least 2.0-fold between the screens (Figure 5A).
Heatmap Figure 5B shows unsupervised clustering of transcripts
obtained for the ALDHbri+ ESCC cells 48 h after KDM4C
knockdown or mock transfection. GO analysis was used to
functionally annotate differentially expressed genes and demonstrated
that the overlapped down-regulated genes were generally enriched for
functions in aldehyde dehydrogenase (NAD) activity, transcription
factor binding/pluripotency maintenance, cell cycle regulation and
differentiation. Selected genes that can be organized by function or
family are illustrated in heatmap Figure 5C.
Among these genes are a number of known pluripotency-associated
genes, including Pou5f1, c-Myc, SOX2 and KLF4 which were chosen
for further analysis because they had known functions for stemness
maintenance, making them more desirable targets for later functional
analysis. qPCR was carried out to validate this finding and results
were concordant with the microarray results (Figure 5D1). Among
these genes, SOX2, a key transcription factor important for the
maintenance of pluripotency and self-renewal of ES cells was
strikingly down-regulated and was chosen as a target for these
studies. A representative example of TICs that were stained for both
KDM4C and SOX2 is shown in Figure 5E1.iated gene promoters in response to KDM4C inhibition in ALDHbri+
g KDM4C knockdown (via transfection with control shRNA,
o CaA for various concentrations, as indicated. Cells were then
thylation forms to determine H3K9 methylation levels at the SOX2,
g PCR amplification products corresponding to the SOX2 promoter
r the di- (H3K9me2) or the trimethylated form of H3K9 (H3K9me3)
of H3K9 methylation levels at the SOX2 promoter after KDM4C
cies (% input) are shown with error bars based on standard errors
set as 100% (not depicted in graphs) for each set of assays. (C)
corresponding to the c-Myc promoter region is shown. Specific
d form of H3K9 were used. (D) ChIP analysis of H3K9 methylation
real-time PCR. (E) ChIP analysis of H3K9 methylation levels at the
rious concentrations, as indicated, as quantified by real-time PCR.
lated forms are shownwith error bars based on SEs calculated from
t the c-Myc promoter after 48 h of exposure or not exposure to CaA
CR. (G) Xenotransplants from each group were collected, Western
lots of H3K9me3 and H3K9me2 protein expression in whole tissue
. Note the increase in H3K9me3 and H3K9me2 immunoreactivity in
loading control. (H) Expression of SOX2 and H3K9me3 protein in
ns were counterstained with hematoxylin (blue nuclei). Note the
munostaining in CaA-treated xenografts compared with controls
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and GO analysis heatmap (Figure 5C), we also confirmed a significant
decrease in the expression of the diverse members of aldehyde
dehydrogenase family in ALDHbri+ TICs, including ALDH1A1,
ALDH1A3, ALDH16A1, ALDH6A1,ALDH7A1 and ALDH4A1
(Figure 5D2). A representative example of TICs that were stained for
both KDM4C and ALDH1 is shown in Figure 5E2.
KDM4C Inhibition is Involved in the Maintenance of
H3K9me3 at the Pluripotency-Associated Genes Locus
To test the hypothesis that down-regulation of pluripotency-
associated genes during KDM4C inhibition is linked to histone
modifications, we investigated whether the demethylase inhibitor
CaA affect selected global histone methylation states in ALDHbri+
cells, using AlphaLISA Assay. We observed that, treatment of
ALDHbri+ cells with CaA for 48 h led to a dramatic increase of
H3K9me3 levels dose-dependently, whereas H3K4me2 and
H3K4me1 levels did not change significantly (Figure S3A).
Subsequently, we used the technique of quantitative chromatin
immunoprecipitation (qChIP) to probe histone changes at
pluripotency-associated gene promoters during KDM4C inhibition.
ChIP analysis was performed using antibodies that individually
recognize either H3K9me2 or H3K9me3 and the primers amplifying
the regions of SOX2 promoter as indicated in Figure 6A. KDM4C
inhibition was found to cause substantial increases in the levels of
H3K9me3 and H3K9me2 at the SOX2 promoter (Figure 6, A and B).
To extend our study, we screened the promoter regions of other
genes for KDM4C-dependent modulation of the H3K9 methyla-
tion levels and detected KDM4C bind the promoter of c-Myc and
demethylated H3K9me3 and H3K9me2 at its promoter (Figure 6, C
and D). KDM4C binds promoters of the core pluripotency
regulators Pou5f1 providing additional evidence that KDM4C
positively supports ALDHbri+ ESCC TICs pluripotency (Figure S3B)
Representative agarose gel images showing PCR amplification products
corresponding to the SOX2 (Figure S6A), c-Myc (Figure 6C) and
Pou5f1 (Figure S3B) promoter regions are shown. The corresponding
bands were detected in the samples from shKDM4C ALDHbri+ cells,
but remained low in the control cells. Input DNA and anti-IgG
antibody-precipitated DNA were used as positive and negative
controls, respectively. Quantification of H3K9 methylation levels
by qPCR at the promoters of SOX2 (Figure 6B), c-Myc
(Figure 6D) and Pou5f1 (Figure S3B) were also shown.
Subsequently, we performed a ChIP assay using two indepen-
dently generated anti-KDM4C antibodies. The result showed that
KDM4C was bound to the SOX2 promoter (Figure S3C). In
contrast, Jmjd5 showed only a very low or near background level of
binding (Figure S3D). Furthermore, the depletion of KDM4C
using either shRNA construct abolished the KDM4C ChIP signal,
indicating that the antibodies specifically recognized KDM4C
(Figure S3E).
To this end, we performed the ChIP assay using CaA. ALDHbri+
cells were exposed or not exposed to CaA at multiple concentrations
of (5, 10, 20 μM) CaA for 48 h, and chromatin was prepared for
analysis. Results revealed that treatment of ALDHbri+ cells with CaA
led to a marked increase in levels of di-, and trimethylated H3K9
histones on both SOX2 (Figure 6E and S3F) and c-Myc promoters
(Figure 6F and S3G), consistent with decreased SOX2 and c-Myc
expression in these cells, whereas no effect was detected on a
non-target, anti-GST. The data support a role of KDM4C inpositively regulating a subset of pluripotency-associated genes by
demethylation of H3K9me3 and H3K9me2 at their promoters.
To examine whether CaA blockage of the KDM4C demethylase
function affects xenograft tumor growth via epigenetic modifications,
we determine whether CaA affects H3K9 methylation globally
in vivo. H3K9 methylation levels were analyzed in histone extracts
prepared from ALDHbri+-derived xenograft tumors after exposure to
CaA. Western blot analysis (Figure 6G) showed that global di- or the
trimethylated forms of H3K9 were significantly increased in
CaA-treated xenografts than in controls. To examine whether the
effects reflect the expression of target genes involved in the repression
of growth, we analyzed expression of SOX2 and H3K9me3 by using
IHC analysis from xenograft tumors. The expression level of SOX2
was significantly decreased whereas the H3K9me3 was increased in
CaA-treated xenografts than in controls (Figure 6H). To test whether
CaA treatment promoted the alteration in epigenetic marks on SOX2
promoter, we examined the status of the H3K9me3 marks in
xenografts. A substantial increase was found in the H3K9me3 at the
SOX2 promoters (Figure S3H) These studies suggest that blockage
of the KDM4C axis via CaA has potential to decrease ESCC TICs
in vivo by epigenetic modification at promoters of target genes.
SOX2 is Involved inMediating the Inhibitory Effects of KDM4C
Inactivation on ESCC ALDHbri+ Cells
Studies employing in vitro culture of ALDHbri+ cells have shown
that inhibition of SOX2 expression causes decreased clonogenicity
and self-renewal (Figure 7, A and B), which is similar to the
phenotype that was observed when KDM4C was depleted, suggesting
that SOX2 serves as a primary and key direct target of KDM4C
inactivation for growth inhibition in ESCC ALDHbri+ cells.
To further determine whether reduced expression of SOX2 is
responsible for the growth inhibition caused by KDM4C inactiva-
tion, we tried to co-transfected a SOX2 or vector control expression
plasmid with KDM4Csh or shRNA constructs in ALDHbri+ cells.
Ectopic expression of SOX2 led to a significant resistance of these
cells to KDM4C inhibition as compared with controls as shown that
ALDHbri+ cells co-transfected with a SOX2 vector plasmid and
KDM4Csh constructs were found to retain TICs ALDH activity
(Figure 7C), thus, cells could similarly initiate spheroid formation
(Figure 7D) and expand in subsequent serial propagations
(Figure 7E). The depletion of KDM4C was equally efficient in the
control and SOX2-overexpressing ALDHbri+ cells (Data not shown).
This excludes the possibility that the phenotypic differences were due
to insufficient depletion of KDM4C.
Additionally, ectopic expression of SOX2 plasmid blocked the
effects of CaA on the ALDHbri+ populations as shown by the
maintenance of the ALDHbri+ populations (Figure 7F) and
sphere-forming ability (Figure 7G) after treatment with the inhibitor.
The rescued phenotype in SOX2-overexpressing ALDHbri+ cells was
also supported by engraftment capability analyses. These cells
maintained the ability to engraft when injected subcutaneously in
immunodeficient animals as compared to control cells upon CaA
treatment (Figure 7H). Taken together, the rescue result indicates
that SOX2 can compensate for the loss of KDM4C.
KDM4C Pathway Correlates with Adverse Pathologic Phenotypes
and Poor Overall Survival in ESCC Patients
We characterized the expression of KDM4C in patient ESCC
by Quantitative real-time PCR (qPCR) analysis. As shown in
Figure 7. SOX2 is the key downstream effector of KDM4C responsible for maintaining ALDHbri+ ESCC cells. (A) Representative images of spheres
formedbyALDHbri+ cells transducedwithLV-cor LV-shSOX2. (Scalebar = 50μm,Upperpanel). Esosphere formationanalysis ofALDHbri+ cells reveal
SOX2knockdown lead to a reduction in clonogenic efficiency (Lowerpanel). (B) ALDHbri+ cellswere capableof self-renewal in vitro, as shownbysimilar
esosphere-initiating capacity in serial passages. Significant reduction in the self-renewal of ALDHbri+ cells upon SOX2 knockdown is shown. (C-E)
EnforcedSOX2over-expression could rescue the differentiation phenotype induced byKDM4Cdepletion. ALDHbri+ cellswere transfectedwith vehicle
or a SOX2-overexpressing vector and challenged with shRNA directing against KDM4C. The cells were subjected to Aldefluor analysis, spheroid
formation testandexpand insubsequentserialpropagations toexamineself-renewal.Note the rescueandthemaintenanceofALDHbri+populations (C),
spheroid formation (D) and self-renewal capability (E) in SOX2-overexpressing-KDM4C-shRNA treated cells. Little or no rescuewas observedwhen the
cellswerechallengedwithvehicle. (F-G)EnforcedSOX2over-expressioncould rescue thedifferentiationphenotype inducedbyCaAtreatment.ALDHbri+
cells were transfectedwith vehicle or a SOX2-overexpressing vector and treatedwith CaA. The cells were subjected to Aldefluor analysis and spheroid
formation test. Note the rescue and the maintenance of ALDHbri+ populations (F) and spheroid formation capability (G) in SOX2-overexpressing-CaA
treated cells. Little or no rescue was observed when the cells were challenged with vehicle. (H) Enforced SOX2 over-expression could rescue the
engraftment capability uponCaA treatment. ALDHbri+ cellswere transfectedwith vehicle or SOX2-overexpressing vector and subjected to engraftment
capability analyses.Note themaintenanceofengraftment capability inSOX2-overexpressingcells uponCaA treatment. Little or no rescuewasobserved
when the cells were challenged with vehicle. Data shown are the mean ± S.E.M. of at least three independent experiments. *P⩽0.05; **P⩽0.01.
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significantly higher than that in adjacent normal tissues (P = .001,
Figure S4A). Afterward, Spearman rank correlation coefficient test
and linear tendency test were conducted. It revealed that there is a
statistically significant linear correlation between the expression
of KDM4C and SOX2 (P b .001, r = 0.874) (Figure S4B and
Table VI) as well as KDM4C and ALDH1 (P = .002, r = 0.644)
(Figure S4C and Table VI) in ESCC.
To investigate the relationship between KDM4C pathway
expression and clinicopathological characteristics, a series of archived
ESCC specimens with multistage and differentiation were co-stained
with specific antibodies for KDM4C, SOX2 and ALDH1 and
the levels of expression were analyzed (Figure S4D). As shown in
Figure S4D, an increase in KDM4C in the cytoplasmic and nuclear
areas of ESCCs compared with normal mucosa was observed.
Interestingly, the cancer cells at the tumor-host interface exhibited
intense staining for the presence of KDM4C and ALDH1 in some
cases (Figure S4E). These suggested that the KDM4C pathway-
positive cells might be mainly localized at the invading tumor front
thus endowed with adverse pathologic phenotypes.
As shown in Table VII, KDM4C protein was detectable with
significantly higher frequency in advanced T-grade ESCCs than in
tumors with early stage. Moreover, KDM4C increased concomitantly
with tumor TNM stage. In addition, the numbers of sample positive
for KDM4C were significantly greater in poorly-differentiated tumors
compared with those well-differentiated ones (Table VII). There was
no significant association between KDM4C expression and age,
location, gross pathology and tumor size (Table VII). Kaplan–Meier
analyses of overall survival showed that patients carrying tumors with
increased expression of KDM4C had a significantly worse five-year
overall survival than patients with tumors that had decreased
expression (P = .0082, Figure S4F). Moreover, patients with
co-expression of KDM4C and SOX2 had a poorer prognosis (P =
.0006, Figure S4G).
Overall, our findings suggest that KDM4C signaling cascade
contributes to adverse pathologic phenotypes and poor overall
survival of ESCC.
Discussion
The KDM4/JMJD2 JmjC-containing histone lysine demethylases
(KDM4A-KDM4D), which selectively remove the methyl group(s)
from tri/dimethylated lysine 9/36 of H3 in a Fe2+ and
α-KG-dependent manner and are involved in a plethora of cellular
processes [3]. For example, several lines of evidence suggest that
KDM4C, originally identified as a gene amplified in ESCC cell lines
plays a role in malignant transformation [3]. Subsequent studies have
shown amplifications of KDM4C in a metastatic lung sarcomatoid
carcinoma, medulloblastomas, breast cancers, primary mediastinal B
cell lymphomas, Hodgkin lymphomas, and acute myeloid leukemia
[5,9,13,23–25]. While KDM4C is considered an interesting drug
target for cancer therapy, this demethylase has also been reported to
fulfill vital functions during embryonic and postnatal development
[14–16]. Our study described increased expression of KDM4C in the
ESCC ALDHbri+ TICs and its involvement in TICs maintenance was
rigorously demonstrated by a variety of standard assays including
esospheres in vitro, tumorigenic potential in vivo and serial
transplantations/passaging.
Based on sequence homologies and architectural similarities, these
JmjC-domain containing demethylases shared similar enzymaticactivities most likely exert overlapping functions roles at some
developmental stages. Recently, it reported that KDM4A and
KDM4C exert a strong overlap in the binding patterns in mESCs
[26], neural stem cells [27] and transformed leukemic cells [5], where
they exert redundant functions in preventing accumulation of
H3K9me3 and H3K36me3. Likewise, our functional studies of
KDM4C and the closely related KDM4A are complicated by the fact
that the ALDHbri+ populations express both demethylases. Although,
we failed to detect other JmjC domain-containing histone demethy-
lases, including JMJD1A, KDM4B or KDM4D were up-regulated in
this population. This raises the question as to whether functional
redundancy exists within KDM4A and KDM4C in our cellular
systems. Thus, a meaningful study of target gene specificity using
shRNA technology was applied to investigate the relative contribu-
tions of the two demethylases to ALDHbri+ TICs maintenance.
However, our results differ from the published observations in the
following conceptually important ways. The first indication that
KDM4C and KDM4A play non-redundant roles came from
variations in expression levels of the subfamily members. Immuno-
histochemical studies of KDM4C and KDM4A in ESCC tissues have
demonstrated tissue- and cell-specific expression, with very little
overlap. This might reflect their distinct expression patterns and
non-overlapping biological functions in different individuals. Second,
KDM4A and KDM4Cmay not completely function redundantly but
appear to regulate a distinct set of targets. We demonstrated that
respective knockdown of the demethylases had distinct effects on
gene expression, and depletion of both demethylases generally was not
found to enhance the transcriptional effects. Nevertheless, Gene
Ontology analyses showed that genes with deregulated expression
upon loss of KDM4C were enriched for functions related to various
cellular reprogramming. However, KDM4A does not appear to
participate in maintaining the gene signature typical of pluripotent
state. The fact [26] that this enzyme is dispensable for mESCs
maintenance or mouse embryogenesis seems paradoxical and reveals
cell context type-dependency of KDM4 enzymes effects. Third,
several reports [3,5,26,28] have described KDM4A-dependent
modulation of H3K9me3 at selected tested promoter regions, and
global increases in H3K9me3 have been reported for certain cell
types. Surprisingly, KDM4A knockdown ALDHbri+ cells did not
display comparable increases in H3K9me3 levels at regions analyzed
by ChIP-qPCR. Thus, KDM4A appears to play a minor role in the
regulation of H3K9 tri-methylation at KDM4C bound sites in
ESCCs. Our data is consistent with a recently published report [29]
describing binding specificity of KDM4C from that of the double
Tudor domains of KDM4A and KDM4C in ESCC KYSE150 cell
line and also consistent with the possibility that KDM4A has roles in
transcriptional regulation that are uncoupled from H3K9me3
methylation [4]. Investigation of the relative roles of KDM4A and
KDM4C in ESCC TICs maintenance provides additional evidence
for distinct functions of the two enzymes. We indicate that KDM4C
inhibition decreases the clonogenicity and self-renewal of ALDHbri+
ESCC TICs. However, we did not observe impaired esospheres-
forming capacity or serial transplantations efficiency in vitro or
substantial decrease in the population of ALDHbri+ cells upon genetic
deletion of KDM4A in ESCC cells. Furthermore, a comparable
phenotype was observed for ALDHbri+ cells in the absence of
KDM4C and cells devoid of both KDM4A and KDM4C (our
unpublished data). These data imply that KDM4C had vital
functions in ESCC ALDHbri+ TICs maintenance that are not shared
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redundancy or interaction between KDM4C and KDM4A in our
cellular context than previously anticipated. The discrepancy further
highlights the importance of understanding in which cellular context
and protein complexes these demethylases are acting and suggests that
differences in genetic backgrounds, culture conditions and the use of
knockdown constructs versus the study of knockout cells must be
taken into account.
Considering the significant implication of KDM4 demethylases
in the development of various diseases, a thorough understanding
of their molecular mechanism and effective therapeutic inhibition
is of considerable interest. On the basis of the three-dimensional
structures available and studies of their catalytic mechanisms,
a number of KDM4 inhibitors have been identified and
reported [10–12].
Caffeic acid (3,4-dihydroxycinnamic acid, CaA), a naturally
occurring hydroxycinnamic acid derivatives, is an active component
in the phenolic propolis extract and also in a wide variety of plants
[30]. CaA was identified as several known JmjC histone demethylase
inhibitors, which inhibits KDM4C with an IC50 value of about 10
μM [20]. Our studies reveal the identification of the novel inhibitors
of KDM4C with therapeutic implications for ESCC, as demonstrated
by dose-inhibition response of the proportion of ALDHbri+ cells in
xenografts to this compound. Likewise, recent studies [30–32]
published the use of CaA and its derivative, Caffeic acid phenethyl
ester (CAPE) to inhibit CSCs-like properties in human breast cancer
and malignant human keratinocyte. Although the molecular
mechanisms underlying remain largely uninvestigated in this studies,
the demonstration that CaA can inhibit the demethylation activity of
KDM4C and KDM4C confers stem cell-like characteristics such as
the ability to form mammospheres in breast CSCs [13] could be used
as an argument to propose that this study provided some proof of
concept for targeting the CSCs by KDM4C demethylase inhibitors.
One limitation of our study is that we cannot exclude additional
targets of CaA based on its role as a pan-selective JmjC demethylases
inhibitor [20]. For example, the fact that the microarray data are
highly non-overlapping suggests that CaA hits other targets besides
KDM4C. Indeed, CaA also exerts inhibitory effects on other
pathways, such as DNA methylation, lipid synthesize and itself is
an antioxidant [30]. Although it can be hard to reconcile, the
discrepancy at least could be due to the fact that none of studies have
been shown to be selective for the KDM4C demethylase thus far,
although several mechanistic-based inhibitors toward the catalytic
JmjC domain of the histone demethylases have been studied in recent
years [11,12,33]. Based on the studies presented here, we hope that
the available subfamily-specific chemical inhibitors will be refined
potent and selective lysine demethylase inhibitors will be identified so
that, in a few years, we can test the feasibility of using
KDM4C-specific inhibitors for the treatment of ESCC.
Jin et al. [8] recently published the identification of a new chemical
compound, SD70 by chemical library screening and obtained data
that characterize it as a potential KDM4C inhibitor for cancer
therapy. Likewise, Cheung et al. [9] provided the molecular and
preclinical evidence for the potential clinical utility of SD70 in MLL
leukemia. While our manuscript was being prepared for
re-submission, we further demonstrated the therapeutic potentials
of targeting KDM4C by SD70 in ESCC ALDHbri+ cells to rule out
other inhibitory effects from CaA treatment. We provide evidence
that SD70 causes pronounced changes in ESCC ALDHbri+ cellcharacteristics manifested by dose-dependent inhibition of progenitor
formation and self-renewal in serum-free medium, reduction in clonal
growth in soft agar and concurrent significant decrease in ALDHbri+
content, all signs of decreased malignancy potential. Furthermore,
experiments showed that this small-molecule inhibitor could also
remarkable lower tumor burdens and extend the disease latency,
particularly in the ALDHbri+ population-derived xenograft in vivo
model (our unpublished data), thus holding potential promise for
ultimate use in ESCC therapy. Although we cannot exclude the
possibility that CaA or SD70 also inhibits other JmjC demethylases,
these results could also be faithfully reproduced using an independent
KDM4C shRNA approach on the ESCC ALDHbri+ cells phenoco-
pying effects of the two chemical inhibitors, and therefore suggesting
that KDM4C might represent as at least one target mediating CaA
and SD70 effects. Another important limitation is the focus on
experiments presented mainly relied on the usage of shRNA, which
could have the disadvantage of substantial off-target effects.
Importantly, the conclusions presented in our study are based on
the finding that KDM4C knockdown did not affect the expression
of KDM4A.
A main finding of this study is that, we identified a number of
KDM4C target genes in ESCC TICs that have important roles in the
maintenance of pluripotency and are part of the core ES cell
transcriptional circuitry (Figure S5), consistent with the previous
study in early embryos and ES cells in which KDM4C is required for
maintenance of pluripotency and occupies key pluripotency and
epigenetic modifier genes [15]. Additionally, accumulating evidence
has supported the existence of TICs share important characteristics
with embryonic and normal tissue stem cells, including extensive
self-renewal and stemness signatures [19,34].
Interestingly, our result suggests that the specific demethylation of
H3K9Me3 by KDM4C at the SOX2 promoter may be required in
the ESCC TICs maintenance. However, we observed that the SOX2
rescue was only partial, as some differentiated phenotype were still
observed. Thus it is possible that other SOX2-independent
mechanisms exist for KDM4C in regulating the ESCC TICs.
Thus, further investigation for other regulatory targets that also could
be important in TIC physiology is warranted. Meanwhile, our finds
demonstrated that, of a subset of isozymes in this family, a number of
ALDH isozymes, including ALDH1A1, ALDH1A3 and ALDH3A1
were differentially expressed in ESCC ALDHbri+ cells with or without
KDM4C inhibition. Different ALDH isoenzymes has been identified
contribute to the elevated ALDH activity in TICs of varied origin
thus has been employed as putative CSC markers in multiple tumor
types, with focus on ALDH1 and ALDH3A1 [19]. In this regard, it is
logical to hypothesize that KDM4C play roles in TIC physiology is
proposed to, in part, through ALDH isozymes family. Thus, further
investigations of the roles of ALDH1A isozymes in the KDM4C
pathway are clearly warranted. These findings together provide
insight into mechanisms by which KDM4C maintains the epigenetic
state of specific target programs and highlight KDM4C-mediated
epigenetic modifications as a means by which it is involved in
orchestrating TIC physiology in ESCC.
To our knowledge, this is the first study to identify ALDH1 as
a marker of ESCC TICs from freshly resected tumor specimens
and, most importantly, is one of the few studies to associate
KDM4C expression in ESCC with an adverse pathologic
phenotypes and a poor prognosis. In addition, we first study to identify
and characterize the molecular signatures and biological properties
608 KDM4C and Enhancing SOX2 Expression Yuan et al. Neoplasia Vol. 18, No. 10, 2016associated with KDM4C in ESCC ALDHbri+ TICs, which make
KDM4C a novel and attractive therapeutic target for human ESCC. The
characterization of molecular targets downstream of KDM4C in ESCC
TICs in this study should provide not only a better understanding of the
mechanisms regulating this specific subpopulation but also novel insights
that could be used for the development of more effective cancer therapies
for the treatment of this disease.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Authors' Contributions
Conception and design: Shegan Gao, Xiang Yuan, Gang Liu;
Development of methodology: Xiang Yuan, Jinyu Kong, Zhikun
Ma, Na Li, Ruinuo Jia, Yiwen Liu;
Acquisition of data (provided animals, acquired and managed
patients, provided facilities, etc.): Fuyou Zhou, Xiang Yuan, Jinyu
Kong, Zhikun Ma, Na Li, Ruinuo Jia, Yiwen Liu;
Analysis and interpretation of data (e.g., statistical analysis,
biostatistics, computational analysis): Xiang Yuan, Jinyu Kong,
Zhikun Ma, Na Li, Ruinuo Jia, Yiwen Liu;
Writing, review, and/or revision of the manuscript: Xiang Yuan,
Gang Liu, Qimin Zhan;
Administrative, technical, or material support (i.e., reporting or
organizing data, constructing databases): Qimin Zhan, Shegan Gao.
Study supervision: Gang Liu, Qimin Zhan, Shegan Gao.
Acknowledgments
We wish to thank Yinming Liang in Xinxiang Medical University for
excellent technical help and for critical reading of an early version of
the manuscript. We thank Dr. Shimada in Kyoto University for
generously providing us with ESCC cell lines.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.08.005.References
[1] Rassouli FB, Matin MM, and Saeinasab M (2015). Cancer stem cells in human
digestive tract malignancies. Tumour Biol .
[2] Yuan X, He J, Sun F, and Gu J (2013). Effects and interactions of MiR-577 and
TSGA10 in regulating esophageal squamous cell carcinoma. Int J Clin Exp Pathol
6, 2651–2667.
[3] Kooistra SM and Helin K (2012). Molecular mechanisms and potential
functions of histone demethylases. Nat Rev Mol Cell Biol 13, 297–311.
[4] Berry WL and Janknecht R (2013). KDM4/JMJD2 histone demethylases:
epigenetic regulators in cancer cells. Cancer Res 73, 2936–2942.
[5] Agger K, Miyagi S, Pedersen MT, Kooistra SM, Johansen JV, and Helin K
(2016). Jmjd2/Kdm4 demethylases are required for expression of Il3ra and
survival of acute myeloid leukemia cells. Genes Dev 30, 1278–1288.
[6] Hillringhaus L, Yue WW, Rose NR, Ng SS, Gileadi C, Loenarz C, Bello SH,
Bray JE, Schofield CJ, and Oppermann U (2011). Structural and evolutionary
basis for the dual substrate selectivity of human KDM4 histone demethylase
family. J Biol Chem 286, 41616–41625.
[7] Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka ES, Lienard BM, Bray
JE, Savitsky P, Gileadi O, and von Delft F, et al (2007). Crystal structures of
histone demethylase JMJD2A reveal basis for substrate specificity. Nature 448,
87–91.
[8] Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J,
and Ohgi KA, et al (2014). Chem-seq permits identification of genomic targets of
drugs against androgen receptor regulation selected by functional phenotypic
screens. Proc Natl Acad Sci U S A 111, 9235–9240.[9] Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG,
Lenhard B, Chan LC, and So CW (2016). Targeting Aberrant Epigenetic
Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Cancer Cell 29, 32–48.
[10] Rotili D, Tomassi S, Conte M, Benedetti R, Tortorici M, Ciossani G,
Valente S, Marrocco B, Labella D, and Novellino E, et al (2014).
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C
and lysine-specific demethylases display high anticancer activities. J Med
Chem 57, 42–55.
[11] Suzuki T and Miyata N (2011). Lysine demethylases inhibitors. J Med Chem 54,
8236–8250.
[12] Yu V, Fisch T, Long AM, Tang J, Lee JH, Hierl M, Chen H, Yakowec P,
Schwandner R, and Emkey R (2012). High-throughput TR-FRET assays for
identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases. J
Biomol Screen 17, 27–38.
[13] Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP,
and Yang ZQ (2009). Genomic amplification and oncogenic properties of
the GASC1 histone demethylase gene in breast cancer. Oncogene 28,
4491–4500.
[14] Loh YH, Zhang W, Chen X, George J, and Ng HH (2007). Jmjd1a and Jmjd2c
histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells.
Genes Dev 21, 2545–2557.
[15] Wang J, Zhang M, Zhang Y, Kou Z, Han Z, Chen DY, Sun QY, and Gao S
(2010). The histone demethylase JMJD2C is stage-specifically expressed in
preimplantation mouse embryos and is required for embryonic development. Biol
Reprod 82, 105–111.
[16] Katoh Y and Katoh M (2007). Comparative integromics on JMJD2A, JMJD2B
and JMJD2C: preferential expression of JMJD2C in undifferentiated ES cells. Int
J Mol Med 20, 269–273.
[17] Luo Y, Dallaglio K, Chen Y, RobinsonWA, Robinson SE, McCarter MD,Wang
J, Gonzalez R, Thompson DC, and Norris DA, et al (2012). ALDH1A isozymes
are markers of human melanoma stem cells and potential therapeutic targets.
Stem Cells 30, 2100–2113.
[18] Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M,
Jacquemier J, Viens P, Kleer CG, and Liu S, et al (2007). ALDH1 is a marker of
normal and malignant human mammary stem cells and a predictor of poor
clinical outcome. Cell Stem Cell 1, 555–567.
[19] Ma I and AL A (2011). The role of human aldehyde dehydrogenase in normal
and cancer stem cells. Stem Cell Rev 7, 292–306.
[20] Nielsen AL, Kristensen LH, Stephansen KB, Kristensen JB, Helgstrand C, Lees
M, Cloos P, Helin K, Gajhede M, and Olsen L (2012). Identification
of catechols as histone-lysine demethylase inhibitors. FEBS Lett 586,
1190–1194.
[21] Lu Y, Chu A, Turker MS, and Glazer PM (2011). Hypoxia-induced
epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol 31,
3339–3350.
[22] Zhao Y, Bao Q, Schwarz B, Zhao L, Mysliwietz J, Ellwart J, Renner A, Hirner H,
Niess H, and Camaj P, et al (2014). Stem cell-like side populations in esophageal
cancer: a source of chemotherapy resistance and metastases. Stem Cells Dev 23,
180–192.
[23] Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, Actor
B, Mincheva A, Pietsch T, and Lichter P, et al (2006). Comprehensive genomic
analysis of desmoplastic medulloblastomas: identification of novel amplified
genes and separate evaluation of the different histological components. J Pathol
208, 554–563.
[24] Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S,
Kongkham PN, Peacock J, and Dubuc A, et al (2009). Multiple recurrent genetic
events converge on control of histone lysine methylation in medulloblastoma.
Nat Genet 41, 465–472.
[25] Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz
G, Ngo VN, and Shaffer AL, et al (2010). Cooperative epigenetic modulation by
cancer amplicon genes. Cancer Cell 18, 590–605.
[26] Wu L, Wary KK, Revskoy S, Gao X, Tsang K, Komarova YA, Rehman J, and
Malik AB (2015). Histone Demethylases KDM4A and KDM4C Regulate
Differentiation of Embryonic Stem Cells to Endothelial Cells. Stem Cell Rep 5,
10–21.
[27] Cascante A, Klum S, Biswas M, Antolin-Fontes B, Barnabe-Heider F, and
Hermanson O (2014). Gene-specific methylation control of H3K9 and H3K36
on neurotrophic BDNF versus astroglial GFAP genes by KDM4A/C regulates
neural stem cell differentiation. J Mol Biol 426, 3467–3477.
Neoplasia Vol. 18, No. 10, 2016 KDM4C and Enhancing SOX2 Expression Yuan et al. 609[28] Pedersen MT, Kooistra SM, Radzisheuskaya A, Laugesen A, Johansen JV,
Hayward DG, Nilsson J, Agger K, and Helin K (2016). Continual removal of
H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal
and early development. EMBO J 35, 1550–1564.
[29] Pedersen MT, Agger K, Laugesen A, Johansen JV, Cloos PA, Christensen J, and
Helin K (2014). The demethylase JMJD2C localizes to H3K4me3-positive
transcription start sites and is dispensable for embryonic development. Mol Cell
Biol 34, 1031–1045.
[30] Li Y, Jiang F, Chen L, Yang Y, Cao S, Ye Y, Wang X, Mu J, Li Z, and Li L
(2015). Blockage of TGFbeta-SMAD2 by demethylation-activated miR-148a is
involved in caffeic acid-induced inhibition of cancer stem cell-like properties
in vitro and in vivo. FEBS Open Bio 5, 466–475.[31] Omene CO, Wu J, and Frenkel K (2012). Caffeic Acid Phenethyl Ester (CAPE)
derived from propolis, a honeybee product, inhibits growth of breast cancer stem
cells. Invest New Drugs 30, 1279–1288.
[32] Yang Y, Li Y, Wang K, Wang Y, Yin W, and Li L (2013). P38/NF-kappaB/snail
pathway is involved in caffeic acid-induced inhibition of cancer stem cells-like properties
and migratory capacity in malignant human keratinocyte. PLoS One 8, e58915.
[33] Maes T, Carceller E, Salas J, Ortega A, and Buesa C (2015). Advances in the
development of histone lysine demethylase inhibitors. Curr Opin Pharmacol 23,
52–60.
[34] De Los AA, Ferrari F, Xi R, Fujiwara Y, Benvenisty N, Deng H, Hochedlinger K,
Jaenisch R, Lee S, and Leitch HG, et al (2015). Hallmarks of pluripotency.
Nature 525, 469–478.
